Healthcare Industry News: Egalet Corporation
News Release - November 16, 2016
Atrin Pharmaceuticals Elects Jeffrey M. Dayno, MD to Board of DirectorsDOYLESTOWN, Pa., Nov. 16, 2016 -- (Healthcare Sales & Marketing Network) -- Atrin Pharmaceuticals, Inc. today announced the election of Jeffrey M. Dayno, M.D., chief medical officer of Egalet Corporation, to the Atrin board of directors.
"Jeffrey Dayno joins the Atrin board with an 18 years of senior track record of senior pharmaceutical industry experience at both global and emerging biopharmaceutical companies in the realm of medical affairs," said Oren Gilad, Ph.D., Atrin Pharmaceuticals President and Chief Executive Officer. "He brings to our board a keen perspective on all aspects of pharmaceutical medicine, clinical development strategy and trial design, and drug regulatory affairs that will serve our company well as we prepare to advance our novel ATR inhibitors into clinical development. I am very pleased to welcome Jeff to the Atrin board of directors."
Prior to joining Egalet, a specialty medical pharmaceutical company focused on innovative treatments for pain, in July 2014, Dr. Dayno was vice president, global medical affairs at ViroPharma, Inc., from August 2011 to May 2014. Prior to joining ViroPharma, Dr. Dayno was the chief medical officer at Labopharm, Inc., a drug delivery technology company based in Montreal, Canada, where he first started working in the field of abuse-deterrent opioid product development. Before Labopharm, he was vice president of medical affairs at Cephalon, Inc., from 2005 to 2010. Dr. Dayno started his career in the pharmaceutical industry in 1998 at Merck & Co., Inc., where he spent 7 years in positions of increasing responsibility in the medical and scientific affairs division. Before moving into leadership roles in the pharmaceutical and biotechnology industry, he spent 10 years in academic and clinical medicine, involved in patient care, teaching, and clinical research. Dr. Dayno earned his medical degree from Temple University School of Medicine.
About Atrin Pharmaceuticals
Atrin Pharmaceuticals is a privately held biopharmaceutical company, based in Doylestown, PA, that aims to change the way cancer is being treated. The company is engaged in the discovery and development of innovative treatments for cancer. Atrin's most advanced program is focused on a new class of compounds that are highly specific inhibitors of ATR, a key mediator of DNA repair. Atrin is further assembling a pipeline of additional drug candidates, identified via the company's proprietary, human cell-based, high-throughput screening platform, Atrize™. Applicable to both drug discovery/development and the evaluation of patient-specific treatments, Atrize enables the rapid identification and evaluation of compounds that are effective in inhibiting cancer cell viability without adversely affecting healthy cells. For more information on the company, please visit our website at http://atrinpharma.com/.
Source: Atrin Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.